Patents by Inventor Cliona M. Rooney

Cliona M. Rooney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12102652
    Abstract: Embodiments of the disclosure include methods and compositions for enhancing expansion of immune cells for immunotherapy. In particular embodiments, immune cells, such as T-cells, express a constitutively active cytokine receptor in which the transmembrane and endodomains are able to provide an activating signal separately from any input to the corresponding exodomain to which they are operably linked. In specific embodiments, the transmembrane and endodomain from IL-7R? is utilized with the exodomain of CD34.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: October 1, 2024
    Assignee: Baylor College of Medicine
    Inventors: Thomas C. T. Shum, Stephen M. G. Gottschalk, Bilal Omer, Cliona M. Rooney
  • Publication number: 20240318137
    Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.
    Type: Application
    Filed: June 3, 2024
    Publication date: September 26, 2024
    Inventors: Juan F. VERA, Cliona M. ROONEY, Ann M. LEEN, John R. WILSON
  • Publication number: 20240301028
    Abstract: Polypeptides comprising: (i) an MHC class I ? polypeptide association domain, (ii) a transmembrane domain, and (iii) a signalling domain comprising an ITAM-containing sequence are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using such polypeptides.
    Type: Application
    Filed: April 24, 2024
    Publication date: September 12, 2024
    Applicant: Baylor College of Medicine
    Inventors: David Quach, Cliona M. Rooney
  • Patent number: 11999969
    Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: June 4, 2024
    Assignees: Wilson Wolf Manufacturing, Baylor College of Medicine
    Inventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson
  • Patent number: 11981923
    Abstract: The present invention concerns methods of generating CTLs that are able to target at least one antigen from two or more viruses. The method includes exposing mixtures of peptides for different antigens to the same plurality of PBMCs and, at least in certain aspects, expanding the cells in the presence of IL4 and IL7.
    Type: Grant
    Filed: April 18, 2022
    Date of Patent: May 14, 2024
    Assignee: Baylor College of Medicine
    Inventors: Ann Marie Leen, Juan Fernando Vera Valdes, Cliona M. Rooney, Ulrike Gerdemann
  • Publication number: 20240084255
    Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.
    Type: Application
    Filed: November 16, 2023
    Publication date: March 14, 2024
    Inventors: Juan F. VERA, Cliona M. ROONEY, Ann M. LEEN, John R. WILSON
  • Publication number: 20240002797
    Abstract: Production and use of novel therapeutic cells, called T-Vehicles, in the allogeneic Adoptive Cell Therapy setting allows a wide range of therapeutic benefits to accrue with minimal or no risk of GVHD. T-Vehicles are created from donor T cells that are altered to contain therapeutic attributes that do not include their native antigen receptors and can deliver therapeutic benefits irrelevant of their native antigen specificity. T-Vehicles can possess highly restricted native antigen specificity that renders them unable to recognize antigens present on normal cells and incapable of initiating GVHD, making them ideal transport vehicles to deliver various therapeutic attributes in vivo. In essence, production and use of T-Vehicles is a paradigm shift that opens the door to therapeutic application of T cells in ways not previously contemplated, independent of whether or not there is an HLA match between the donor and the recipient.
    Type: Application
    Filed: May 17, 2023
    Publication date: January 4, 2024
    Inventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson
  • Publication number: 20230383250
    Abstract: Production and use of novel therapeutic cells, called T-Vehicles, in the allogeneic Adoptive Cell Therapy setting allows a wide range of therapeutic benefits to accrue with minimal or no risk of GVHD. T-Vehicles are created from donor T cells that are altered to contain therapeutic attributes that do not include their native antigen receptors and can deliver therapeutic benefits irrelevant of their native antigen specificity. T-Vehicles can possess highly restricted native antigen specificity that renders them unable to recognize antigens present on normal cells and incapable of initiating GVHD, making them ideal transport vehicles to deliver various therapeutic attributes in vivo. In essence, production and use of T-Vehicles is a paradigm shift that opens the door to therapeutic application of T cells in ways not previously contemplated, independent of whether or not there is an HLA match between the donor and the recipient.
    Type: Application
    Filed: May 17, 2023
    Publication date: November 30, 2023
    Inventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson
  • Patent number: 11821002
    Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.
    Type: Grant
    Filed: March 7, 2022
    Date of Patent: November 21, 2023
    Assignees: Baylor College of Medicine, Wilson Wolf Manufacturing
    Inventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson
  • Publication number: 20230357721
    Abstract: The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane.
    Type: Application
    Filed: July 18, 2023
    Publication date: November 9, 2023
    Inventors: Ann Marie Leen, Ulrike Gerdemann, Cliona M. Rooney, Juan F. Vera Valdes, John R. Wilson
  • Publication number: 20230220097
    Abstract: Treatment and prevention of cancer using virus-specific immune cells, comprising a chimeric antigen receptor (CAR) or nucleic acid encoding a CAR, wherein the CAR comprises: (i) an antigen-binding domain which binds specifically to CD30, (ii) a transmembrane domain, and (iii) a signalling domain, wherein the signalling domain comprises: (a) an amino acid sequence derived from the intracellular domain of CD28, and (b) an amino acid sequence comprising an immunoreceptor tyrosine-based activation motif (ITAM), is disclosed.
    Type: Application
    Filed: April 27, 2021
    Publication date: July 13, 2023
    Inventors: David H. Quach, Cliona M. Rooney, Carlos A. Ramos
  • Publication number: 20230210901
    Abstract: Embodiments of the disclosure include methods and compositions for inhibiting the immune suppressive tumor microenvironment using cell therapy wherein the cells express a chimeric protein having an extracellular domain that binds TRAIL-R2 and an intracellular domain that in specific embodiments comprises one or more costimulatory domains that enhance activity of the cells upon activation. In specific embodiments, the chimeric protein comprises an scFv that targets TRAIL-R2 and an intracellular region that comprises a costimulatory domain from 4-1BB. In particular embodiments, the cells also express a therapeutic protein, such as a chimeric antigen receptor.
    Type: Application
    Filed: April 21, 2021
    Publication date: July 6, 2023
    Inventors: Valentina Hoyos, Saisha Nalawade, Ann Marie Leen, Helen E. Heslop, Juan Fernando Vera Valdes, Malcolm Brenner, Cliona M. Rooney
  • Publication number: 20230172986
    Abstract: Treatment and prevention of diseases/conditions characterised by an alloreactive immune response using virus-specific immune cells, comprising a chimeric antigen receptor (CAR) or nucleic acid encoding a CAR, wherein the CAR comprises: (i) an antigen-binding domain which binds specifically to CD30, (ii) a transmembrane domain, and (iii) a signalling domain, wherein the signalling domain comprises: (a) an amino acid sequence derived from the intracellular domain of CD28, and (b) an amino acid sequence comprising an immunoreceptor tyrosine-based activation motif (ITAM), is disclosed.
    Type: Application
    Filed: April 27, 2021
    Publication date: June 8, 2023
    Inventors: David H. Quach, Cliona M. Rooney, Carlos A. Ramos
  • Publication number: 20230167187
    Abstract: Virus-specific immune cells, comprising a chimeric antigen receptor (CAR) or nucleic acid encoding a CAR, wherein the CAR comprises: (i) an antigen-binding domain which binds specifically to CD30, (ii) a transmembrane domain, and (iii) a signalling domain, wherein the signalling domain comprises: (a) an amino acid sequence derived from the intracellular domain of CD28, and (b) an amino acid sequence comprising an immunoreceptor tyrosine-based activation motif (ITAM), are disclosed. Also disclosed are methods for producing and compositions comprising such cells.
    Type: Application
    Filed: April 27, 2021
    Publication date: June 1, 2023
    Inventors: David H. Quach, Cliona M. Rooney, Carlos A. Ramos
  • Publication number: 20230114971
    Abstract: The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane.
    Type: Application
    Filed: December 6, 2022
    Publication date: April 13, 2023
    Inventors: Ann Marie Leen, Ulrike Gerdemann, Cliona M. Rooney, Juan F. Vera Valdes, John R. Wilson
  • Patent number: 11590218
    Abstract: Embodiments of the disclosure concern methods and compositions for immunotherapy for human papillomavirus infection and diseases associated therewith. In specific embodiments, methods concern production of immune cells that target one or more antigens of HPV16 and/or HPV18, including methods with stimulation steps that employ IL-7 and IL-15, but not IL-6 and/or IL-12. Other specific embodiments utilize stimulations in the presence of certain cells, such as costimulatory cells and certain antigen presenting cells.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: February 28, 2023
    Assignee: Baylor College of Medicine
    Inventors: Carlos A. Ramos, Cliona M. Rooney, Neeharika Narala
  • Publication number: 20220401478
    Abstract: Methods for generating/expanding populations of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen are disclosed, the methods comprising stimulating immune cells specific for an EBV lytic antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens. Also disclosed are populations of immune cells comprising immune cells specific for an EBV lytic antigen expanded according to such methods, and uses thereof.
    Type: Application
    Filed: April 9, 2020
    Publication date: December 22, 2022
    Inventors: Cliona M. Rooney, Sandhya Sharma
  • Publication number: 20220282218
    Abstract: The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane.
    Type: Application
    Filed: May 26, 2022
    Publication date: September 8, 2022
    Inventors: Ann Marie Leen, Ulrike Gerdemann, Cliona M. Rooney, Juan F. Vera Valdes, John R. Wilson
  • Publication number: 20220251508
    Abstract: The present invention concerns methods of generating CTLs that are able to target at least one antigen from two or more viruses. The method includes exposing mixtures of peptides for different antigens to the same plurality of PBMCs and, at least in certain aspects, expanding the cells in the presence of IL4 and IL7.
    Type: Application
    Filed: April 18, 2022
    Publication date: August 11, 2022
    Inventors: Ann Marie Leen, Juan Fernando Vera Valdes, Cliona M. Rooney, Ulrike Gerdemann
  • Publication number: 20220251509
    Abstract: Embodiments of the disclosure concern methods and compositions for immunotherapy for diseases and malignancies associated with viruses other than HPV or with non-virus-associated diseases and malignancies, such as wherein the VST encodes a CAR specific for a non-viral cancer and the VST can be stimulated in vitro or in vivo using viruses, viral vaccines or oncolytic viruses. In specific embodiments, methods concern production of immune cells that target one or more antigens of HIV, EBV, CMV, adenovirus, vaccinia virus, and/or VZV, including methods with stimulation steps that employ IL-7 and IL-15, but not IL-2, IL-4, or both. Other specific embodiments utilize stimulations in the presence of certain cells, such as costimulatory cells and certain antigen presenting cells.
    Type: Application
    Filed: April 28, 2022
    Publication date: August 11, 2022
    Inventors: Cliona M. Rooney, Natalia Lapteva Doyle, Sandhya Sharma, Dimitrios Wagner